Risk factors for intracranial hemorrhage and nonhemorrhagic stroke after fibrinolytic therapy (from the GUSTO-i trial)

Am J Cardiol. 2004 Feb 15;93(4):458-61. doi: 10.1016/j.amjcard.2003.10.043.

Abstract

Of 592 patients in the Global Utilization of Streptokinase and tPA for Occluded Arteries-I trial who had a stroke during initial hospitalization, the risk for intracranial hemorrhage was significantly greater in those with recent facial or head trauma (odds ratio 13.0, 95% confidence interval 3.4 to 85.5); dementia was additionally associated with an increased risk for intracranial hemorrhage (odds ratio 3.4, 95% confidence interval 1.2 to 10.2). Because facial or head trauma may greatly influence treatment decisions, this risk factor should be incorporated into models designed to estimate the risks and benefits of fibrinolytic therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Case-Control Studies
  • Chi-Square Distribution
  • Female
  • Humans
  • Intracranial Hemorrhages / epidemiology*
  • Intracranial Hemorrhages / etiology
  • Male
  • Middle Aged
  • Myocardial Infarction / drug therapy*
  • Odds Ratio
  • Prospective Studies
  • Risk Factors
  • Streptokinase / adverse effects*
  • Streptokinase / therapeutic use
  • Stroke / epidemiology*
  • Stroke / etiology
  • Thrombolytic Therapy / adverse effects*
  • Tissue Plasminogen Activator / adverse effects*
  • Tissue Plasminogen Activator / therapeutic use

Substances

  • Streptokinase
  • Tissue Plasminogen Activator